Sanjay K Srivastava

Sanjay K Srivastava serves as Distinguished Professor and Department Chairman of Immunotherapeutics and Biotechnology at Texas Tech University Health Sciences Center in Abilene, Texas. His leadership role oversees academic and research initiatives within this specialized department focused on advancing biotechnological approaches to disease treatment.

His research spans Cancer Immunotherapy, Molecular Oncology, and Drug Repurposing, with particular emphasis on exploiting existing pharmaceuticals for novel anti-cancer applications. Dr. Srivastava investigates how repurposed drugs modulate tumor microenvironments, disrupt critical signaling pathways like Hippo-YAP and PKA-Gli1, and enhance immune responses against aggressive malignancies including glioblastoma, pancreatic cancer, and triple-negative breast cancer.

Analysis of his 2020-2025 publication record reveals consistent innovation in identifying drug-cancer pathway interactions, with significant contributions in glioblastoma immunity modulation, pancreatic tumor microenvironment reprogramming, and metastatic breast cancer suppression. His work demonstrates how compounds like moxidectin, milbemycin oxime, and atovaquone target specific molecular mechanisms to inhibit tumor progression across multiple cancer types.

While Dr. Srivastava actively contributes as a peer reviewer for top-tier journals including Nature Cell Biology and Oncogene, available information does not detail scientific awards, student mentorship activities, grant funding, or laboratory infrastructure specifics.